Navigation Links
Vasogen Announces First Quarter 2008 Results
Date:4/3/2008

16,725 16,725

Contributed surplus 22,979 22,744

Deficit (387,103) (381,783)

-----------------------------------------------------------------------

18,271 23,356

Future operations

Commitments and contingencies

Subsequent events

-------------------------------------------------------------------------

$ 22,890 $ 28,050

-------------------------------------------------------------------------

-------------------------------------------------------------------------

VASOGEN INC.

(A DEVELOPMENT STAGE COMPANY)

Interim Consolidated Statements of Operations, Deficit and Comprehensive

Income

(In thousands of Canadian dollars, except per share amounts)

(Unaudited)

-------------------------------------------------------------------------

Period from

December 1,

Three months ended 1987 to

February 29, February 28, February 29,

2008 2007 2008

-------------------------------------------------------------------------

Expenses:

Research and development $ 2,778 $ 3,023 $ 241,695

General and administration 2,681 3,588 119,909

Foreign exchange loss (gain) 203 (134) 11,173

-------------------------------------------------------------------------

Loss before the undernoted (5,662) (6,477) (372,777)

Interest expense on senior

conv
'/>"/>

SOURCE Vasogen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
2. Vasogen Announces Third Quarter 2007 Results
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. Vasogen Provides an Update on ACCLAIM-II Preparations
5. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
6. Vasogen to Conduct Year-end 2007 Conference Call
7. Vasogen Announces 2007 Year-End Results
8. The Lancet Publishes Vasogens ACCLAIM Results
9. Vasogens Research Published in European Journal of Neuroscience
10. Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel
11. Vasogen Provides Update on ACCLAIM II Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... According to Jeff Howell, Partner of Nidea ... new development in Downtown Toronto is expanding at a ... 755 storeys of new development last week (including three ... dominating the Toronto skyline for the foreseeable future in ... for new development. , As the Toronto city council ...
(Date:9/15/2014)... 16, 2014 Cancer Immunotherapy ... Adoptive T-cell Therapies is a new market research ... the three principal types of therapeutics that have ... in cancer immunotherapy (which is often called "immuno-oncology") ... and Adoptive cellular immunotherapy. , The regular ...
(Date:9/15/2014)... fast when a patient has sepsis, a life-threatening condition ... blood -- often too fast for antibiotics to help. ... developed by a team at Harvard,s Wyss Institute for ... treat sepsis. , "Even with the best current ... at least 30 percent of the time," said Mike ...
(Date:9/15/2014)... , Sept. 15, 2014 Zymo ... viral transport solution for safe ambient temperature storage ... molecular testing. Importantly, the infectivity of agents in such ... maintaining the integrity of the viral nucleic acids ... the recent Ebola epidemic in West ...
Breaking Biology Technology:ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 2ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 2Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 4Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 5Blood-cleansing biospleen device developed for sepsis therapy 2Blood-cleansing biospleen device developed for sepsis therapy 3Blood-cleansing biospleen device developed for sepsis therapy 4Safe storage and transport of Ebola, Mers-CoV, and other viruses: Groundbreaking viral inactivation solution capable of preserving nucleic acids 2Safe storage and transport of Ebola, Mers-CoV, and other viruses: Groundbreaking viral inactivation solution capable of preserving nucleic acids 3
... 14 At the Board of Directors,meeting held ... of,$.115 per share. The dividend is payable on ... 31, 2007. About Sigma-Aldrich: Sigma-Aldrich is a ... and organic chemical products and kits,are used in ...
... Summertime equals fun for a lot of,folks. But ... typical,summer fare could also mean aggravating their sensitive ... IBS," has more on,what people with IBS can ... from,ruining their celebrations. Listen to this report ...
... 15 /PRNewswire-FirstCall/,-- Shire plc (LSE: SHP, NASDAQ: SHPGY, ... the waiting period under,Hart-Scott-Rodino Antitrust Improvements Act of ... (human TGF BETA 3) from Renovo Group plc,(LSE: ... with its terms, the,License Agreement became effective on ...
Cached Biology Technology:Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3) 2Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3) 3
(Date:9/16/2014)... impact that spelled doom for the dinosaurs 66 million ... to a much greater extent than their deciduous peers, ... results are published in the journal PLOS Biology ... trove of thousands of fossilized leaves of angiosperms ... able to reconstruct the ecology of a diverse plant ...
(Date:9/16/2014)... a new football season and another commercial cargo flight ... spacecraft is scheduled to blast off to the orbital ... company,s fourth contracted mission to the complex. , Included ... research investigations sponsored by the Center for the Advancement ... managing the U.S. National Laboratory on the space station, ...
(Date:9/16/2014)... Keystone XL pipeline (KXL) would likely increase oil sands ... surveyed by the non-profit organization Near Zero. The results ... Impact," and includes both supporters and opponents of the ... sands could lead to significantly higher greenhouse gas emissions, ... respond. , "This report examines three main scenarios ...
Breaking Biology News(10 mins):Meteorite that doomed dinosaurs remade forests 2Meteorite that doomed dinosaurs remade forests 3Meteorite that doomed dinosaurs remade forests 4CASIS research set for launch aboard SpaceX mission to space station 2CASIS research set for launch aboard SpaceX mission to space station 3Keystone XL would likely raise oil sands production and greenhouse gas emissions 2
... has identified a genetic variant that substantially increases the ... populations. The study, published by Cell Press on August ... , associates a deletion on chromosome 3 with increased ... that affects 1% of the world population. Characterized by ...
... scientists have been able to measure the amount of water that ... result -- 285 billion metric tons, or 285 cubic kilometers of ... over half the volume of Lake Erie, which is the world,s ... of the water flowing through the Amazon River every year, and ...
... Swine Flu. Rabies. These are emerging infectious diseases where ... another and now infect humans. This is a phenomenon ... to determine what drives it. Gary McCracken, a ... head in Ecology and Evolutionary Biology, is one of ...
Cached Biology News:Large risk schizophrenia marker revealed 2First satellite measurement of water volume in Amazon floodplain 2First satellite measurement of water volume in Amazon floodplain 3UT professor uncovers clues into how viruses jump from hosts 2
Spastin (Sp 3G11/1)...
mCD-1 10 transcription reactions...
... Rabbits x 2 , ... bleed x1 /each , Immunizations/Boost injections ... (app. 5 ml) x1 /each , ... /each , Final Bleed ~ 100 ml blood ...
Mouse VCAM-1/CD106 MAb (Clone 112702)...
Biology Products: